Title: Comparison the effects and side effects of Covid-19 vaccination in patients with
inflammatory bowel disease (IBD); A systematic scoping review
Version: 0 Date: 27 Jul 2022
Reviewer's report:
I think this manuscript is pretty interesting. The Authors aimed at evaluating the benefits and
side effects of vaccines in patiens with IBD.
It is really interesting to analyze this events, since  it has already been demonstrated that the
fear of side effects is the most frequent among the reasons given by patients with IBD for their
vaccine hesitancy.
Among these studies, I would cite a big Italian study in which  vaccine hesitancy among IBD
patients was investigated: a survey was sent by patients'association. More than 1200 patients
answered to the survey and the fear of adverse   effects was the main reason for refusal
(approximately 70 %).
A native speaker  could add value to this article.
Did they measure in every studies  antibody  to the spike (rather than to the nucleocapside)?
Which cut off of antibody title was assessed to define immunity ? and when? (2 weeks after
1st dose?)
Did they  evaluated in any study been antibodies in Crohn and RCU separately?
Which were the characteristics of the patients who had an exacerbation of the IBD after the
vaccine? (e.g.,  immunosoppressive therapy, more severe disease activity)
Is there a difference in hospitalization rate after the first dose versus the second dose?
Some other comments:
In the abstract there is a misprint "the studies's findings"
In the discussion the paragraph starting with "The laboratory activity of IBD..." is not clear.
Title: Comparison the effects and side effects of Covid-19 vaccination in patients with
inflammatory bowel disease (IBD); A systematic scoping review
Version: 0 Date: 27 Jul 2022
Reviewer's report:
I think this manuscript is pretty interesting. The Authors aimed at evaluating the benefits and
side effects of vaccines in patiens with IBD.
It is really interesting to analyze this events, since  it has already been demonstrated that the
fear of side effects is the most frequent among the reasons given by patients with IBD for their
vaccine hesitancy.
Among these studies, I would cite a big Italian study in which  vaccine hesitancy among IBD
patients was investigated: a survey was sent by patients'association. More than 1200 patients
answered to the survey and the fear of adverse   effects was the main reason for refusal
(approximately 70 %).
A native speaker  could add value to this article.
Did they measure in every studies  antibody  to the spike (rather than to the nucleocapside)?
Which cut off of antibody title was assessed to define immunity ? and when? (2 weeks after
1st dose?)
Did they  evaluated in any study been antibodies in Crohn and RCU separately?
Which were the characteristics of the patients who had an exacerbation of the IBD after the
vaccine? (e.g.,  immunosoppressive therapy, more severe disease activity)
Is there a difference in hospitalization rate after the first dose versus the second dose?
Some other comments:
In the abstract there is a misprint "the studies's findings"
In the discussion the paragraph starting with "The laboratory activity of IBD..." is not clear.
Please review this paper.
user
Title: Comparison the effects and side effects of Covid-19 vaccination in patients with
inflammatory bowel disease (IBD); A systematic scoping review
Version: 0 Date: 27 Jul 2022
Reviewer's report:
I think this manuscript is pretty interesting. The Authors aimed at evaluating the benefits and
side effects of vaccines in patiens with IBD.
It is really interesting to analyze this events, since  it has already been demonstrated that the
fear of side effects is the most frequent among the reasons given by patients with IBD for their
vaccine hesitancy.
Among these studies, I would cite a big Italian study in which  vaccine hesitancy among IBD
patients was investigated: a survey was sent by patients'association. More than 1200 patients
answered to the survey and the fear of adverse   effects was the main reason for refusal
(approximately 70 %).
A native speaker  could add value to this article.
Did they measure in every studies  antibody  to the spike (rather than to the nucleocapside)?
Which cut off of antibody title was assessed to define immunity ? and when? (2 weeks after
1st dose?)
Did they  evaluated in any study been antibodies in Crohn and RCU separately?
Which were the characteristics of the patients who had an exacerbation of the IBD after the
vaccine? (e.g.,  immunosoppressive therapy, more severe disease activity)
Is there a difference in hospitalization rate after the first dose versus the second dose?
Some other comments:
In the abstract there is a misprint "the studies's findings"
In the discussion the paragraph starting with "The laboratory activity of IBD..." is not clear.
assistant